unique long acting therapeutic peptides . underlying all conjuchem compounds are bioconjugation platforms called drug affinity complex dac and preformed conjugate drug affinity complex pc dac . when applied to a given peptide dac and pc dac can create new drugs with similar therapeutic activities but with significantly longer durations of activity and improved safety profiles . press releases wednesday september 14 2011 conjuchem initiates phase 2 study of diabetes drug tuesday august 30 2011 conjuchem resumes operations led by dr. patrick soon shiong monday june 8 2009 conjuchem reports data on pc dac tm exendin 4 and pc insulin at 2009 american diabetes association meeting about us technology pipeline news partnering conjuchem llc . all rights reserved terms of use website design hane chow inc. .